Major response to everolimus in melanoma with acquired imatinib resistance

J Clin Oncol. 2012 Feb 1;30(4):e37-40. doi: 10.1200/JCO.2011.37.9644. Epub 2011 Dec 12.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzamides
  • Drug Resistance, Neoplasm
  • Everolimus
  • Female
  • Humans
  • Imatinib Mesylate
  • Melanoma / drug therapy*
  • Middle Aged
  • Piperazines / pharmacology*
  • Pyrimidines / pharmacology*
  • Sirolimus / analogs & derivatives*
  • Sirolimus / therapeutic use

Substances

  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Everolimus
  • Sirolimus